Press Releases

Laverock Therapeutics today announces it is to present new data on its innovative gene-silencing platform at the European Society of Gene & Cell Therapy (ESGCT) Conference in Rome 22-25 October.

Laverock Therapeutics today announces significant progress in the industrialisation and validation of its technology platform enabling broadening of its potential therapeutic application. 

Laverock Therapeutics today announces its conference attendance programme for the remainder of 2024.

Laverock Therapeutics announces the appointment of Ali Elsley as Finance Director. Laverock has also significantly grown its team to 24 people, representing growth of 50% over the past year.

Laverock Therapeutics raises £13.5M to develop unique gene silencing platform for programmable advanced therapies

Laverock Therapeutics secures Innovate UK award to advance immune effector cell therapeutics programme using GEiGS® technology

Laverock Therapeutics founded to develop the next generation of programmable cell therapies